Results 11 to 20 of about 253,192 (255)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods.
P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila   +17 more
doaj   +2 more sources

Exploring the Role of Interleukin-6 Receptor Inhibitor Tocilizumab in Patients with Active Rheumatoid Arthritis and Periodontal Disease. [PDF]

J Clin Med, 2021
Background: The aim of our study was to explore the influence of weekly subcutaneous administration of interleukin-6 (IL-6) receptor inhibitor tocilizumab (TCZ) on periodontal status in a local longitudinal study of patients with rheumatoid arthritis (RA) and periodontal disease (PD).
Ancuța C, Chirieac R, Ancuța E, Țănculescu O, Solomon SM, Fătu AM, Doloca A, Iordache C.   +7 more
europepmc   +4 more sources

B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them.

Научно-практическая ревматология, 2019
The clinical efficacy and safety of interleukin-6 (IL-6) receptor blockade have been well studied, but the data on the impact of therapeutic inhibition of IL-6 on B cells are scarce and contradictory.
E. V. Gerasimova, T. V. Popkova, A. P. Aleksankin, A. V. Martynova, E. L. Nasonov   +4 more
doaj   +3 more sources

In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor [PDF]

Bioscience, Biotechnology, and Biochemistry, 2021
ABSTRACT Interleukin-6 (IL-6) binds to the IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study, we performed systematic evolution of ligands by exponential enrichment and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 n m,
Ando, Takehiro, Yamamoto, Mizuki, Takamori, Yukio, Tsukamoto, Keita, Fuji, Daisuke, Kawakami, Takashi   +5 more
openaire   +2 more sources

Interleukin 6 Receptor Inhibitor Levilimab in the Treatment of Rheumatoid Arthritis

Effective Pharmacotherapy, 2022
The inhibitors of the biological effects of interleukin 6 (IL-6) are the most actively developing group of biologics for the treatment of rheumatoid arthritis (RA) due to pleiotropic effects of this most important pro-inflammatory cytokine, which stimulates a number of processes that play an important role in the pathogenesis of RA.
D.E. Karateev, E.L. Luchikhina
openaire   +2 more sources

Dynamics of modified cardiovascular risk factors in patients with rheumatoid arthritis on the background of 5-year therapy with an interleukin 6 receptor inhibitor

Научно-практическая ревматология
The effect of an inhibitor of interleukin (IL) 6 receptors on the state of the cardiovascular system in patients with rheumatoid arthritis (RA) remains poorly understood, especially with its long-term use.The aim – to study the effect of therapy with the
E. V. Gerasimova, T. V. Popkova, I. G. Kirillova, D. A. Gerasimova, E. L. Nasonov   +4 more
doaj   +3 more sources

Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis [PDF]

BMC Neurology, 2021
Abstract Background Interleukin-6-receptor inhibitors like Tocilizumab and Satralizumab are showing promising results in the treatment of Neuromyelitis Optica spectrum disorder (NMOSD). We aimed to investigate the efficacy and safety of various Interleukin-6-receptor inhibitors in the management of NMO/NMOSD.
Sanjeev Kharel, Suraj Shrestha, Rajeev Ojha, Neha Guragain, Rakesh Ghimire   +4 more
openaire   +3 more sources

Spontaneous Regression of Metastatic Colorectal Cancer Following Discontinuation of an Interleukin-6 Receptor Inhibitor: A Case Report. [PDF]

Surg Case Rep
Miyake E, Taniguchi F, Nosaka M, Mouri K, Sato M, Kajioka H, Ogawa T, Watanabe M, Katsuda K, Iseki A, Sato Y, Tanakaya K, Aoki H.   +12 more
europepmc   +2 more sources

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease [PDF]

Clinical and Experimental Immunology, 2005
SummaryThe presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93·5 ng/ml; interquartile range, 26–125 ng/ml; inactive disease, 81 ng/ml,
K, Mitsuyama, N, Tomiyasu, A, Suzuki, K, Takaki, H, Takedatsu, J, Masuda, H, Yamasaki, S, Matsumoto, O, Tsuruta, A, Toyonaga, M, Sata   +10 more
openaire   +2 more sources

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer, 2023
Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R ...
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Kaysia Ludford, Emma J Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M Zeman, Rafee Talukder, Namrata Singh, Sarah H Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey Weber, Jean H Tayar, Maria E Suarez-Almazor, Noha Abdel-Wahab, Adi Diab   +32 more
openaire   +3 more sources